Perioperative Considerations Patients With T2DM on SGLT2i Perioperative Considerations Patients With T2DM on SGLT2i
SGLT2 inhibitors create new management challenges for anesthesiologists. What are the unique considerations for diabetic patients taking these agents perioperatively?Anesthesia &Analgesia
This study examined the associations between risk of ASD in offspring and maternal T1D, T2D, and GDM.
CONCLUSION: We found no significant long-term analgesic or quality of life benefit from IV lidocaine relative to control infusion for chronic peripheral neuropathic pain. TRIAL REGISTRATION: clinicaltrials.gov (NCT01669967); registered 22 June, 2012. PMID: 31098961 [PubMed - as supplied by publisher]
Conclusion: The prevalence of CPTP was high. It significantly impacts health-related QOL.
Conditions: Coronary Heart Disease; Anemia; Bronchial Asthma; Stroke; Epilepsy; Parkinson's Disease; Heart Rhythm Disorders; Alzheimer's Disease; Neuromuscular Diseases; Diabetes; Chronic Heart Failure; Chronic Obstructive Pulmonary Disease; Chronic Kidney Diseases Intervention: Sponsors: Russian Federation of Anesthesiologists and Reanimatologists; Kuban State Medical University Not yet recruiting
A 57-YEAR-OLD, 112 kg, 168 cm man with a history of poorly controlled type II diabetes mellitus, hypertension, hyperlipidemia, and obstructive sleep apnea presented to the authors ’ institution for evaluation of intermittent chest pain that typically lasted less than 1 minute and occurred at rest. His chest pain was not correlated with exercise nor did it substantially affect his activities of daily living. The patient also reported chronic, daily headaches that were treate d with acetaminophen-caffeine.
ADULTS older than 55 years are increasingly being affected by cardiovascular disease, cerebrovascular disease, and diabetes mellitus with a growing risk of perioperative complications.1 As newer therapies undoubtedly are improving survival, the growing aged population with ubiquitous cardiovascular disease will be subjected to surgery sometime during their lifetime.2 The likelihood of having surgery is quadrupled in this group when contrasted with the general population.3,4 As the world demographics change, the surgical burden, an “indivisible, indispensable part of health care,” is expected to grow exponentially.
Mariana Teles1*†, Miguel Oliveira2†, Ismael Jerez-Cepa3, Lorena Franco-Martínez4, Asta Tvarijonaviciute4, Lluis Tort1‡ and Juan M. Mancera3‡ 1Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain 2Department of Biology, Centre for Environmental and Marine Studies, University of Aveiro, Aveiro, Portugal 3Departamento de Biología, Facultad de Ciencias del Mar y Ambientales, Instituto Universitario de Investigación Marina (INMAR), Campus de Excelencia Internacional del Mar (CEIMAR), Universidad de Cádiz...
CONCLUSION: The DIGG risk score can predict risk-adjusted hospital mortality after EVAR and OR of iAAA in the DIGG register. Improvements with respect to the prediction are desirable for OR and should be strived for by extending the model in the future. PMID: 31053898 [PubMed - as supplied by publisher]
Purpose of review The implications for perioperative management of new oral antihyperglycemic medications and new insulin treatment technologies are reviewed. Recent findings The preoperative period represents an opportunity to optimize glycemic control and potentially to reduce adverse outcomes. There is now general consensus that the optimal blood glucose target for hospitalized patients is approximately 106–180 mg/dl (6–10 mmol/l). Recommendations for the management of antihyperglycemic medications vary among national guidelines. It may not be necessary to cease all antihyperglycemic agents prior to...